Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,766 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune Diseases of the Nervous System Clear all
Completed Not applicable Interventional

Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis

NCT05979688
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Myasthenia Gravis
Interventions
yogic breathing exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Sep 29, 2026, 11:38 PM EDT
Terminated No phase listed Observational

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

NCT02218879
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tecfidera
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Early Phase 1 Interventional

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

NCT00424788
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Plasma exchange, natalizumab treatment
Procedure · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Cleveland, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

NCT01031459
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron (Interferon beta-1b, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 29, 2026, 11:38 PM EDT
Active, not recruiting Phase 1 Interventional

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

NCT05755061
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
Interventions
GEMS Plus, GEMS
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
16 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders

NCT02118805
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Phase 4 Interventional Results available

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

NCT01970410
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
teriflunomide
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
21 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Latham, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational

Functional and Physiological Responses to Lokomat Therapy (Pilot Study)

NCT00883142
View directory record Official record
Conditions
Spinal Cord Injuries, Multiple Sclerosis, Stroke
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 29, 2026, 11:38 PM EDT
Recruiting No phase listed Observational

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

NCT07758270
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Remibrutinib, Ocrelizumab (US)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

An Extension of the TG1101-RMS201 Trial

NCT03381170
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Pasadena, California • Aurora, Colorado • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Results available

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

NCT02760056
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Liothyronine sodium, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational

Biomarkers in Multiple Sclerosis

NCT00325988
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 29, 2026, 11:38 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

NCT05132569
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Tolebrutininb, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Boca Raton, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 29, 2026, 11:38 PM EDT
Recruiting Not applicable Interventional

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

NCT06919900
View directory record Official record
Conditions
Multiple Sclerosis (Relapsing Remitting)
Interventions
Perturbation Training, Treadmill Walking
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 89 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Not applicable Interventional Results available

Self-Directed Positive Psychology Intervention for Newly Diagnosed Multiple Sclerosis

NCT06891937
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Positive psychology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational

Bayer/Cognitive Assessments With Multiple Sclerosis Subjects

NCT00888277
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus

NCT00730002
View directory record Official record
Conditions
Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Magnetic Resonance Angiography (MRA), Magnetic resonance imaging, MRA, diffusion Imaging, perfusion imaging.
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

NCT01933802
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
intrathecal administration of autologous MSC-NP
Biological
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 29, 2026, 11:38 PM EDT
Recruiting Not applicable Interventional

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

NCT05958381
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Transcranial Direct Current Stimulation, Sham transcranial direct current stimulation
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 29, 2026, 11:38 PM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RebiSmart™
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 29, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
69
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 29, 2026, 11:38 PM EDT
Completed No phase listed Observational

Therapeutic Plasma Exchange in MG

NCT01927692
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Skin biopsy, Single Fiber Electromyography
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Sep 29, 2026, 11:38 PM EDT